Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
White arrows indicate accumulation of 18F-SPAL-T-06, suggesting α-synuclein aggregates in the putamen, yellow arrows in the pons, yellow triangle in the cerebellar white matter, and white triangle in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback